Navigation Links
Biorem Reports 2014 Second Quarter Results
Date:8/22/2014

GUELPH, ON, Aug. 22, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results for the three month and six month periods ended June 30, 2014.  Biorem's complete 2014 second quarter financial statements and MD&A have been filed on SEDAR (www.sedar.com).

Financial Summary:Three-months ended

June 30,

Six-months ended

June 30,( in CDN$'000 except per share data)

2014

2013

2014

2013Revenue

2,459

5,010

4,433

9,195Gross profit

56

1,485

385

2,585Ebitda*

(623)

507

(965)

740Net earnings (loss)

(835)

254

(1,366)

223Basic earnings (loss) per share

Diluted earnings (loss) per share

(0.06)

(0.06)

0.02

 0.01

(0.11)

(0.11)

  0.02

  0.01*Earnings before interest, taxes and amortization, a non IFRS financial measure 

Revenues for the quarter totaled $2,459,000, a 25% increase over revenues of $1,974,000 recorded during the first quarter of 2014 and a $2,550,000 or 51% decrease over revenues recorded during the second
'/>"/>

SOURCE Biorem Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DryLet to Attend UpTech Upstream Oil and Gas Summit on October 6-8, 2013 in Alberta to Showcase MB Bioremediation
2. DryLet Technologies Announces Website Launch and New Logo Design for Patented MB Bioremediation
3. Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products
4. Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com
5. Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com
6. Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com
7. Dyadic International Reports Q2 2014 Financial Results
8. Sinovac Reports Unaudited Second Quarter Financial Results
9. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
10. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
11. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... British Columbia , Feb. 27, 2015   ... leader in synthetic biology, today announced it has entered ... (OSF), the pioneering agricultural company behind the Arctic ... Through the acquisition, Intrexon expands its food programs to ... convenient for consumers while providing economic benefit throughout the ...
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine”) (TSX: ... today announced that the U.S. Food and Drug ... designation and Phase I clinical trials of the ... mutual co-development agreement signed with Gilead Life Sciences. ... for the DPX-Survivac. , “We have been in ...
(Date:2/27/2015)... FamilyFarms Group is pleased to announce its valued ... received the 2015 Tomorrow’s Top Producer Horizon Award. The ... 35, who has demonstrated excellence in the business of ... Tomorrow's Top Producer Horizon Award. Every year I look ... and learning from their experiences. It is truly humbling ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
... September 22 Bavarian,Nordic A/S (OMX: BAVA) yesterday presented ... ECCO 15 - 34th ESMO Congress in,Berlin, Germany. , ... II double-blind, prospective randomized,placebo-controlled study of 125 patients with ... Medical Director, BN,ImmunoTherapeutics. , The ...
... , , , MOORESVILLE, ... ANPG), reported today that its wholly-owned subsidiary, EnviroSystems, Inc. ... its collaboration and distribution agreement with Minntech Japan. Minntech ... , , Anpath announced the Minntech Japan ...
... , AUGSBURG, Germany, September 22 ... System for Food and Feed on 8 September,2009, the ... the detection of GM linseed/flax variety FP967/CDC Triffid, which,is ... Additionally, there have been additional EU Rapid Alert announcements,regarding ...
Cached Biology Technology:New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 2New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 3Anpath Group, Inc. Reports Progress in Japanese Market 2Anpath Group, Inc. Reports Progress in Japanese Market 3Accredited Construct Specific PCR Test for Recently Detected Unapproved GM Flax/Linseed FP967/CDC Triffid Available Through Genetic ID 2
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has ... Market Overview" report to their offering. , ... that an individual is who she/he is claiming to be, ... a person,s unique physical characteristics, such as fingerprint, hand or ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... may be bad for your breath, but it,s good for ... of British Columbia. The study, recently published in ... two compounds derived from garlic diallyl sulfide and ajoene ... sakazakii in the production of dry infant formula powder. ...
... Scientists at the University of Massachusetts Medical School ... the short DNA reads produced by next-generation sequencing technologies ... Job Dekker, PhD, and colleagues have shown that entire ... measuring the frequency of interactions between DNA segments and ...
... lowland tropics were once though filled with widespread species, while ... more restricted distributions. That idea is turning out to be ... instead of the rule. A new study describes four species ... to the scientific community as Plica plica . ...
Cached Biology News:University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 2University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 3The collared treerunner is more than a single species 2
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Biology Products: